MRI in multiple sclerosis: What’s inside the toolbox?

Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi

doi:10.1016/j.nurt.2007.08.001

. 2007 Oct;4(4):602–617. doi: 10.1016/j.nurt.2007.08.001

MRI in multiple sclerosis: What’s inside the toolbox?

Mohit Neema ¹, James Stankiewicz ¹, Ashish Arora ¹, Zachary D Guss ¹, Rohit Bakshi ^1,^2,^✉

PMCID: PMC7479680 PMID: 17920541

Summary

Magnetic resonance imaging (MRI) has played a central role in the diagnosis and management of multiple sclerosis (MS). In addition, MRI metrics have become key supportive outcome measures to explore drug efficacy in clinical trials. Conventional MRI measures have contributed to the understanding of MS pathophysiology at the macroscopic level yet have failed to provide a complete picture of underlying MS pathology. They also show relatively weak relationships to clinical status such as predictive strength for clinical progression. Advanced quantitative MRI measures such as magnetization transfer, spectroscopy, diffusion imaging, and relaxometry techniques are somewhat more specific and sensitive for underlying pathology. These measures are particularly useful in revealing diffuse damage in cerebral white and gray matter and therefore may help resolve the dissociation between clinical and conventional MRI findings. In this article, we provide an overview of the array of tools available with brain and spinal cord MRI technology as it is applied to MS. We review the most recent data regarding the role of conventional and advanced MRI techniques in the assessment of MS. We focus on the most relevant pathologic and clinical correlation studies relevant to these measures.

Key Words: Multiple sclerosis, MRI, MR spectroscopy, magnetization transfer, diffusion imaging, spinal cord, brain, iron

References

1.Bakshi R, Minagar A, Jaisani Z, Wolinsky JS. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx. 2005;2:277–303. doi: 10.1602/neurorx.2.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Filippi M, Rocca MA. Conventional MRI in multiple sclerosis. J Neuroimaging. 2007;17:3S–9S. doi: 10.1111/j.1552-6569.2007.00129.x. [DOI] [PubMed] [Google Scholar]
3.Zivadinov R, Leist TP. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging. 2005;15:10S–21S. doi: 10.1177/1051228405283291. [DOI] [PubMed] [Google Scholar]
4.Hickman SJ. Optic nerve imaging in multiple sclerosis. J Neuroimaging. 2007;17:42S–45S. doi: 10.1111/j.1552-6569.2007.00136.x. [DOI] [PubMed] [Google Scholar]
5.Cagnin A, Kassiou M, Meikle SR, Banati RB. Positron emission tomography imaging of neuroinflammation. Neurotherapeutics. 2007;4:443–452. doi: 10.1016/j.nurt.2007.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Buckle GJ. Functional magnetic resonance imaging and multiple sclerosis: the evidence for neuronal plasticity. J Neuroimaging. 2005;15:82S–93S. doi: 10.1177/1051228405284093. [DOI] [PubMed] [Google Scholar]
7.Meier DS, Weiner HL, Guttmann CR. Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential? Neurotherapeutics. 2007;4:485–498. doi: 10.1016/j.nurt.2007.05.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Patola WB, Coulter BA, Chipperfield PM, Lingawi SS. A comparison of conventional spin-echo and fast spin-echo in the detection of multiple sclerosis. J Magn Reson Imaging. 2001;13:657–667. doi: 10.1002/jmri.1093. [DOI] [PubMed] [Google Scholar]
9.Bakshi R, Ariyaratana S, Benedict RH, Jacobs L. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch Neurol. 2001;58:742–748. doi: 10.1001/archneur.58.5.742. [DOI] [PubMed] [Google Scholar]
10.Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology. 2005;236:254–260. doi: 10.1148/radiol.2361040450. [DOI] [PubMed] [Google Scholar]
11.Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology. 2007;68:634–642. doi: 10.1212/01.wnl.0000250267.85698.7a. [DOI] [PubMed] [Google Scholar]
12.Wattjes MP, Lutterbey GG, Harzheim M, et al. Imaging of inflammatory lesions at 3.0 Tesla in patients with clinically isolated syndromes suggestive of multiple sclerosis: a comparison of fluid-attenuated inversion recovery with T2 turbo spin-echo. Eur Radiol. 2006;16:1494–1500. doi: 10.1007/s00330-005-0082-4. [DOI] [PubMed] [Google Scholar]
13.Wattjes MP, Lutterbey GG, Gieseke J, et al. Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol. 2007;28:54–59. [PMC free article] [PubMed] [Google Scholar]
14.Fillippi M, Yousri T, Baratti C, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 1994;44:635–641. doi: 10.1212/wnl.44.4.635. [DOI] [PubMed] [Google Scholar]
15.Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120:2059–2069. doi: 10.1093/brain/120.11.2059. [DOI] [PubMed] [Google Scholar]
16.O’Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain. 1998;121:495–503. doi: 10.1093/brain/121.3.495. [DOI] [PubMed] [Google Scholar]
17.Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346:158–164. doi: 10.1056/NEJMoa011341. [DOI] [PubMed] [Google Scholar]
18.Gauthier SA, Mandel M, Guttmann CR, et al. Predicting short-term disability in multiple sclerosis. Neurology. 2007;68:2059–2065. doi: 10.1212/01.wnl.0000264890.97479.b1. [DOI] [PubMed] [Google Scholar]
19.Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol. 2006;60:236–242. doi: 10.1002/ana.20883. [DOI] [PubMed] [Google Scholar]
20.Li DK, Held U, Petkau J, et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology. 2006;66:1384–1389. doi: 10.1212/01.wnl.0000210506.00078.5c. [DOI] [PubMed] [Google Scholar]
21.Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Brueck W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol. 2001;49:793–796. doi: 10.1002/ana.1053. [DOI] [PubMed] [Google Scholar]
22.Fisher E, Chang A, Fox RJ, et al. Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 2007 Apr 111;[Epub ahead of print]. [DOI] [PubMed]
23.Paolillo A, Pozzilli C, Gasperini C, et al. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disability. J Neurol Sci. 2000;174:85–91. doi: 10.1016/s0022-510x(00)00259-8. [DOI] [PubMed] [Google Scholar]
24.Sailer M, Losseff NA, Wang L, et al. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis: a prospective 18 months follow-up study. Eur J Neurol. 2001;8:37–42. doi: 10.1046/j.1468-1331.2001.00147.x. [DOI] [PubMed] [Google Scholar]
25.Adams H-P, Wagner S, Sobel SF, et al. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. Eur Neurol. 1999;42:52–63. doi: 10.1159/000008069. [DOI] [PubMed] [Google Scholar]
26.Molyneux PD, Brex PA, Fogg C, et al. The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study. Mult Scler. 2000;6:237–240. doi: 10.1177/135245850000600405. [DOI] [PubMed] [Google Scholar]
27.Datta S, Sajja BR, He R, Wolinsky JS, Gupta RK, Narayana PA. Segmentation and quantification of black holes in multiple sclerosis. Neuroimage. 2006;29:467–474. doi: 10.1016/j.neuroimage.2005.07.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions (“black holes”) on T1 spinecho MRI correlates with disease progression in multiple sclerosis. Neurology. 1996;47:1469–1476. doi: 10.1212/wnl.47.6.1469. [DOI] [PubMed] [Google Scholar]
29.van Walderveen MA, Lycklama A, Nijeholt GJ, et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol. 2001;58:76–81. doi: 10.1001/archneur.58.1.76. [DOI] [PubMed] [Google Scholar]
30.Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain. 2003;126:1782–1789. doi: 10.1093/brain/awg182. [DOI] [PubMed] [Google Scholar]
31.van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol. 1998;19:675–683. [PMC free article] [PubMed] [Google Scholar]
32.Brack W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 1997;42:783–793. doi: 10.1002/ana.410420515. [DOI] [PubMed] [Google Scholar]
33.Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain. 1997;120:1149–1161. doi: 10.1093/brain/120.7.1149. [DOI] [PubMed] [Google Scholar]
34.Simon JH, Li D, Traboulsee A, Coyle PK, et al. Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol. 2006;27:455–461. [PMC free article] [PubMed] [Google Scholar]
35.Wolansky LJ, Haghighi MH, Sevdalis E, et al. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial. J Neuroimaging. 2005;15:289–290. doi: 10.1177/1051228405277339. [DOI] [PubMed] [Google Scholar]
36.Datta S, Sajja BR, He R, Gupta RK, Wolinsky JS, Narayana PA. Segmentation of gadolinium-enhanced lesions on MRI in multiple sclerosis. J Magn Reson Imaging. 2007;25:932–937. doi: 10.1002/jmri.20896. [DOI] [PubMed] [Google Scholar]
37.Cotton F, Weiner HL, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology. 2003;60:640–646. doi: 10.1212/01.wnl.0000046587.83503.1e. [DOI] [PubMed] [Google Scholar]
38.Masdeu JC, Moreira J, Trasi S, Visintainer P, Cavaliere R, Grundman M. The open ring: a new imaging sign in demyelinating disease. J Neuroimaging. 1996;6:104–107. doi: 10.1111/jon199662104. [DOI] [PubMed] [Google Scholar]
39.Rovira A, Alonso J, Cucurella G, et al. Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. AJNR Am J Neuroradiol. 1999;20:1939–1945. [PMC free article] [PubMed] [Google Scholar]
40.Roychowdhury S, Maldjian JA, Grossman RI. Multiple sclerosis: comparison of trace apparent diffusion coefficients with MR enhancement pattern of lesions. AJNR Am J Neuroradiol. 2000;21:869–874. [PMC free article] [PubMed] [Google Scholar]
41.Minneboo A, Uitdehaag BM, Ader HJ, Barkhof F, Polman CH, Castelijns JA. Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. Neurology. 2005;65:56–61. doi: 10.1212/01.wnl.0000167538.24338.bb. [DOI] [PubMed] [Google Scholar]
42.Leist TP, Gobbini MI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol. 2001;58:57–60. doi: 10.1001/archneur.58.1.57. [DOI] [PubMed] [Google Scholar]
43.Silver NC, Tofts PS, Symms MR, et al. Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult Scler. 2001;7:75–82. doi: 10.1177/135245850100700201. [DOI] [PubMed] [Google Scholar]
44.Soon D, Tozer DJ, Altmann DR, Tofts PS, Miller DH. Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes. Mult Scler 2007 Apr 27;[Epub ahead of print]. [DOI] [PubMed]
45.McFarland HF, Stone LA, Calabresi PA, Maloni H, Bash CN, Frank JA. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Mult Scler. 1996;2:198–205. doi: 10.1177/135245859600200406. [DOI] [PubMed] [Google Scholar]
46.Rashid W, Davies GR, Chard DT, et al. Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study. Mult Scler. 2007;13:178–185. doi: 10.1177/1352458506070758. [DOI] [PubMed] [Google Scholar]
47.Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet. 1999;353:964–969. doi: 10.1016/s0140-6736(98)03053-0. [DOI] [PubMed] [Google Scholar]
48.Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol. 1998;43:332–339. doi: 10.1002/ana.410430311. [DOI] [PubMed] [Google Scholar]
49.Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimenglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 1993;33:480–489. doi: 10.1002/ana.410330511. [DOI] [PubMed] [Google Scholar]
50.Deloire MS, Touil T, Brochet B, Dousset V, Caille JM, Petry KG. Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. Mult Scler. 2004;10:540–548. doi: 10.1191/1352458504ms1090oa. [DOI] [PubMed] [Google Scholar]
51.Petry KG, Boiziau C, Dousset V, Brochet B. Magnetic resonance imaging of human brain macrophage infiltration. Neurotherapeutics. 2007;4:434–442. doi: 10.1016/j.nurt.2007.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
52.Dousset V, Brochet B, Deloire MS, et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol. 2006;27:1000–1005. [PMC free article] [PubMed] [Google Scholar]
53.McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–127. doi: 10.1002/ana.1032. [DOI] [PubMed] [Google Scholar]
54.Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.”. Ann Neurol. 2005;58:840–846. doi: 10.1002/ana.20703. [DOI] [PubMed] [Google Scholar]
55.Lin A, Ross BD, Harris K, et al. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx. 2005;2:197–214. doi: 10.1602/neurorx.2.2.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
56.Rosen Y, Lenkinski RE. Recent advances in magnetic resonance neurospectroscopy. Neurotherapeutics. 2007;4:330–345. doi: 10.1016/j.nurt.2007.04.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
57.Narayana PA. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging. 2005;15:46S–57S. doi: 10.1177/1051228405284200. [DOI] [PMC free article] [PubMed] [Google Scholar]
58.De Stefano N, Filippi M. MR spectroscopy in multiple sclerosis. J Neuroimaging. 2007;17:31S–35S. doi: 10.1111/j.1552-6569.2007.00134.x. [DOI] [PubMed] [Google Scholar]
59.Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 1994;117:49–58. doi: 10.1093/brain/117.1.49. [DOI] [PubMed] [Google Scholar]
60.Husted CA, Goodin DS, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol. 1994;36:157–165. doi: 10.1002/ana.410360207. [DOI] [PubMed] [Google Scholar]
61.Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain. 2005;128:1016–1025. doi: 10.1093/brain/awh467. [DOI] [PubMed] [Google Scholar]
62.De Stefano N, Matthews PM, Antel JP, et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol. 1995;38:901–909. doi: 10.1002/ana.410380610. [DOI] [PubMed] [Google Scholar]
63.Narayana PA, Doyle TJ, Lai D, et al. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol. 1998;43:56–71. doi: 10.1002/ana.410430112. [DOI] [PubMed] [Google Scholar]
64.Narayanan S, Fu L, Pioro E, De Stefano N, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol. 1997;41:385–391. doi: 10.1002/ana.410410314. [DOI] [PubMed] [Google Scholar]
65.Gonen O, Obemdorfer TA, Inglese M, Babb JS, Herbert J, Grossman RI. Reproducibility of three whole-brain N-acetylaspartate decline cohorts in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2007;28:267–271. [PMC free article] [PubMed] [Google Scholar]
66.Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain. 2004;127:1361–1369. doi: 10.1093/brain/awh153. [DOI] [PubMed] [Google Scholar]
67.Wylezinska M, Cifelli A, Jezzard P, Palace J, Alecci M, Matthews PM. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology. 2003;60:1949–1954. doi: 10.1212/01.wnl.0000069464.22267.95. [DOI] [PubMed] [Google Scholar]
68.Sharma R, Narayana PA, Wolinsky JS. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler. 2001;7:221–226. doi: 10.1177/135245850100700402. [DOI] [PubMed] [Google Scholar]
69.Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain. 2002;125:2342–2352. doi: 10.1093/brain/awf240. [DOI] [PubMed] [Google Scholar]
70.Sastre-Garriga J, Ingle GT, Chard DT, et al. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol. 2005;62:569–573. doi: 10.1001/archneur.62.4.569. [DOI] [PubMed] [Google Scholar]
71.De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain. 1998;121:1469–1477. doi: 10.1093/brain/121.8.1469. [DOI] [PubMed] [Google Scholar]
72.De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001;58:65–70. doi: 10.1001/archneur.58.1.65. [DOI] [PubMed] [Google Scholar]
73.Bonneville F, Moriarty DM, Li BS, Babb JS, Grossman RI, Gonen O. Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2002;233:371–375. [PMC free article] [PubMed] [Google Scholar]
74.Pan JW, Krupp LB, Elkins LE, Coyle PK. Cognitive dysfunction lateralizes with NAA in multiple sclerosis. Appl Neuropsychol. 2001;8:155–160. doi: 10.1207/S15324826AN0803_4. [DOI] [PubMed] [Google Scholar]
75.Ruiz-Pena JL, Pinero P, Sellers G, et al. Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy. BMC Neurol. 2004;4:8–8. doi: 10.1186/1471-2377-4-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
76.Gadea M, Martinez-Bisbal MC, Marti-Bonmati L, et al. Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain. 2004;127:89–98. doi: 10.1093/brain/awh002. [DOI] [PubMed] [Google Scholar]
77.Mathiesen HK, Jonsson A, Tscheming T, et al. Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol. 2006;63:533–536. doi: 10.1001/archneur.63.4.533. [DOI] [PubMed] [Google Scholar]
78.Christodoulou C, Krupp LB, Liang Z, et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology. 2003;60:1793–1798. doi: 10.1212/01.wnl.0000072264.75989.b8. [DOI] [PubMed] [Google Scholar]
79.Horsfield MA. Magnetization transfer imaging in multiple sclerosis. J Neuroimaging. 2005;15:58S–67S. doi: 10.1177/1051228405282242. [DOI] [PubMed] [Google Scholar]
80.Filippi M, Rocca MA. Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve. Neurotherapeutics. 2007;4:401–413. doi: 10.1016/j.nurt.2007.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
81.Hiehle JF, Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium enhanced spinecho images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol. 1995;16:69–77. [PMC free article] [PubMed] [Google Scholar]
82.Karampekios S, Papanikolaou N, Papadaki E, et al. Quantification of magnetization transfer rate and native T1 relaxation time of the brain: correlation with magnetization transfer ratio measurements in patients with multiple sclerosis. Neuroradiology. 2005;47:189–196. doi: 10.1007/s00234-005-1344-1. [DOI] [PubMed] [Google Scholar]
83.Rocca MA, Mastronardo G, Rodegher M, et al. Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. AJNR Am J Neuroradiol. 1999;20:821–827. [PMC free article] [PubMed] [Google Scholar]
84.Iannucci G, Tortorella C, Rovaris M, et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol. 2000;21:1034–1038. [PMC free article] [PubMed] [Google Scholar]
85.De Stefano N, Battaglini M, Stromillo ML, et al. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain. 2006;129:2008–2016. doi: 10.1093/brain/awl152. [DOI] [PubMed] [Google Scholar]
86.Pike GB, De Stefano N, Narayanan S, et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology. 2000;215:824–830. doi: 10.1148/radiology.215.3.r00jn02824. [DOI] [PubMed] [Google Scholar]
87.Silver NC, Lai M, Symms MR, Barker GJ, et al. Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology. 1998;51:758–764. doi: 10.1212/wnl.51.3.758. [DOI] [PubMed] [Google Scholar]
88.Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol. 1998;43:809–814. doi: 10.1002/ana.410430616. [DOI] [PubMed] [Google Scholar]
89.van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999;46:747–754. doi: 10.1002/1531-8249(199911)46:5<747::aid-ana10>3.3.co;2-w. [DOI] [PubMed] [Google Scholar]
90.Chen JT, Kuhlmann T, Jansen GH, et al. Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage. 2007;36:1152–1158. doi: 10.1016/j.neuroimage.2007.03.073. [DOI] [PubMed] [Google Scholar]
91.Filippi M, Campi A, Dousset V, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology. 1995;45:478–482. doi: 10.1212/wnl.45.3.478. [DOI] [PubMed] [Google Scholar]
92.Loevner LA, Grossman RI, Cohen JA, Lexa FJ, Kessler D, Kolson DL. Microscopic disease in normal-appearing white matter on conventional MR imaging in patients with multiple sclerosis: assessment with magnetization-transfer measurements. Radiology. 1995;196:511–515. doi: 10.1148/radiology.196.2.7617869. [DOI] [PubMed] [Google Scholar]
93.Ramio-Torrenta L, Sastre-Garriga J, Ingle GT, et al. Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry. 2006;77:40–45. doi: 10.1136/jnnp.2004.052316. [DOI] [PMC free article] [PubMed] [Google Scholar]
94.Vrenken H, Geurts JJ, Knol DL, et al. Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis. AJNR Am J Neuroradiol. 2006;27:2005–2011. [PMC free article] [PubMed] [Google Scholar]
95.Richert ND, Ostuni JL, Bash CN, Duyn JH, McFarland HF, Frank JA. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR Am J Neuroradiol. 1998;19:1705–1713. [PMC free article] [PubMed] [Google Scholar]
96.Ge Y, Grossman RI, Udupa JK, et al. Magnetization transfer ratio histogram analysis of gray matter in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2001;22:470–475. [PMC free article] [PubMed] [Google Scholar]
97.Audoin B, Davies G, Rashid W, Fisniku L, Thompson AJ, Miller DH. Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis. Mult Scler. 2007;13:483–489. doi: 10.1177/1352458506070450. [DOI] [PubMed] [Google Scholar]
98.Fernando KT, Tozer DJ, Miszkiel KA, et al. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain. 2005;128:2911–2925. doi: 10.1093/brain/awh654. [DOI] [PubMed] [Google Scholar]
99.Davies GR, Ramio-Torrenta L, Hadjiprocopis A, et al. Evidence for gray matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004;75:998–1002. doi: 10.1136/jnnp.2003.021915. [DOI] [PMC free article] [PubMed] [Google Scholar]
100.Sharma J, Zivadinov R, Jaisani Z, et al. A magnetization transfer MRI study of deep gray matter involvement in multiple sclerosis. J Neuroimaging. 2006;16:302–310. doi: 10.1111/j.1552-6569.2006.00054.x. [DOI] [PubMed] [Google Scholar]
101.Oreja-Guevara C, Charil A, Caputo D, Cavarretta R, Sormani MP, Filippi M. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis. Arch Neurol. 2006;63:736–740. doi: 10.1001/archneur.63.5.736. [DOI] [PubMed] [Google Scholar]
102.Iannucci G, Minicucci L, Rodegher M, et al. Correlations between clinical and MRI involvement in multiple sclerosis: assessment using T(1), T(2) and MT histograms. J Neurol Sci. 1999;171:121–129. doi: 10.1016/s0022-510x(99)00259-2. [DOI] [PubMed] [Google Scholar]
103.Davies GR, Altmann DR, Rashid W, et al. Emergence of thalamic magnetization transfer ratio abnormality in early relapsing-remitting multiple sclerosis. Mult Scler. 2005;11:276–281. doi: 10.1191/1352458505ms1166oa. [DOI] [PubMed] [Google Scholar]
104.Khaleeli Z, Sastre-Garriga J, Ciccarelli O, Miller DH, Thompson AJ. Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over one year in early primary progressive MS. J Neurol Neurosurg Psychiatry 2007 Feb 7;[Epub ahead of print]. [DOI] [PMC free article] [PubMed]
105.van Buchem MA, Grossman RI, Armstrong C, et al. Correlation of volumetric magnetization transfer imaging with clinical data in MS. Neurology. 1998;50:1609–1617. doi: 10.1212/wnl.50.6.1609. [DOI] [PubMed] [Google Scholar]
106.Filippi M, Tortorella C, Rovaris M, et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68:157–161. doi: 10.1136/jnnp.68.2.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
107.Cox D, Pelletier D, Genain C, et al. The unique impact of changes in normal appearing brain tissue on cognitive dysfunction in secondary progressive multiple sclerosis patients. Mult Scler. 2004;10:626–629. doi: 10.1191/1352458504ms1095oa. [DOI] [PubMed] [Google Scholar]
108.Ranjeva JP, Audoin B, Au Duong MV, et al. Local tissue damage assessed with statistical mapping analysis of brain magnetization transfer ratio: relationship with functional status of patients in the earliest stage of multiple sclerosis. AJNR Am J Neuroradiol. 2005;26:119–127. [PMC free article] [PubMed] [Google Scholar]
109.Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain. 2006;129:2620–2627. doi: 10.1093/brain/awl208. [DOI] [PubMed] [Google Scholar]
110.Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. Neurotherapeutics. 2007;4:316–329. doi: 10.1016/j.nurt.2007.05.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
111.Goldberg-Zimring D, Mewes AU, Maddah M, Warfield SK. Diffusion tensor magnetic resonance imaging in multiple sclerosis. J Neuroimaging. 2005;15:68–81. doi: 10.1177/1051228405283363. [DOI] [PubMed] [Google Scholar]
112.Horsfield MA, Lai M, Webb SL, et al. Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance. Magn Reson Med. 1996;36:393–400. doi: 10.1002/mrm.1910360310. [DOI] [PubMed] [Google Scholar]
113.Bammer R, Augustin M, Strasser-Fuchs S, et al. Magnetic resonance diffusion tensor imaging for characterizing diffuse and focal white matter abnormalities in multiple sclerosis. Magn Reson Med. 2000;44:583–591. doi: 10.1002/1522-2594(200010)44:4<583::aid-mrm12>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
114.Wening DJ, Brassat D, Droogan AG, et al. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain. 2000;123:1667–1676. doi: 10.1093/brain/123.8.1667. [DOI] [PubMed] [Google Scholar]
115.Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology. 2001;56:304–11. doi: 10.1212/wnl.56.3.304. [DOI] [PubMed] [Google Scholar]
116.Schmierer K, Wheeler-Kingshott CA, Boulby PA, et al. Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage. 2007;35:467–477. doi: 10.1016/j.neuroimage.2006.12.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
117.Henry RG, Oh J, Nelson SJ, Pelletier D. Directional diffusion in relapsing-remitting multiple sclerosis: a possible in vivo signature of Wallerian degeneration. J Magn Reson Imaging. 2003;8:420–426. doi: 10.1002/jmri.10379. [DOI] [PubMed] [Google Scholar]
118.Ciccarelli O, Wening DJ, Wheeler-Kingshott CA, et al. Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology. 2001;56:926–933. doi: 10.1212/wnl.56.7.926. [DOI] [PubMed] [Google Scholar]
119.Ceccarelli A, Rocca MA, Falini A, et al. Normal-appearing white and grey matter damage in MS: A volumetric and diffusion tensor MRI study at 3.0 Tesla. J Neurol. 2007;254:513–518. doi: 10.1007/s00415-006-0408-4. [DOI] [PubMed] [Google Scholar]
120.Coombs BD, Best A, Brown MS, et al. Multiple sclerosis pathology in the normal and abnormal appearing white matter of the corpus callosum by diffusion tensor imaging. Mult Scler. 2004;10:392–397. doi: 10.1191/1352458504ms1053oa. [DOI] [PubMed] [Google Scholar]
121.Cader S, Johansen-Berg H, Wylezinska M, et al. Discordant white matter N-acetylasparate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis. Neuroimage. 2007;36:19–27. doi: 10.1016/j.neuroimage.2007.02.036. [DOI] [PubMed] [Google Scholar]
122.Audoin B, Guye M, Reuter F, et al. Structure of WM bundles constituting the working memory system in early multiple sclerosis: a quantitative DTI tractography study. Neuroimage. 2007;36:1324–1330. doi: 10.1016/j.neuroimage.2007.04.038. [DOI] [PubMed] [Google Scholar]
123.Saindane AM, Law M, Ge Y, et al. Correlation of diffusion tensor and dynamic perfusion MR imaging metrics in normal-appearing corpus callosum: support for primary hypoperfusion in multiple sclerosis. AJNR Am J Neuroradiol. 2007;28:767–772. [PMC free article] [PubMed] [Google Scholar]
124.Wilson M, Tench CR, Morgan PS, Blumhardt LD. Pyramidal tract mapping by diffusion tensor magnetic resonance imaging in multiple sclerosis: improving correlations with disability. J Neurol Neurosurg Psychiatry. 2003;74:203–207. doi: 10.1136/jnnp.74.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
125.Fabiano AJ, Sharma J, Weinstock-Guttman B, Benedict RH, Zivadinov R, Bakshi R. Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. J Neuroimaging. 2003;13:307–314. [PubMed] [Google Scholar]
126.Rovaris M, Gallo A, Valsasina P, et al. Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. Neuroimage. 2005;24:1139–1146. doi: 10.1016/j.neuroimage.2004.10.006. [DOI] [PubMed] [Google Scholar]
127.Droogan AG, Clark CA, Werring DJ, Barker GJ, McDonald WI, Miller DH. Comparison of multiple sclerosis clinical subgroups using navigated spin echo diffusion-weighted imaging. Magn Reson Imaging. 1999;17:653–661. doi: 10.1016/s0730-725x(99)00011-9. [DOI] [PubMed] [Google Scholar]
128.Cercignani M, Iannucci G, Rocca MA, Comi G, Horsfield MA, Filippi M. Pathologic damage in MS assessed by diffusion-weighted and magnetization transfer MRI. Neurology. 2000;54:1139–1144. doi: 10.1212/wnl.54.5.1139. [DOI] [PubMed] [Google Scholar]
129.Caramia F, Pantano P, Di Legge S, et al. A longitudinal study of MR diffusion changes in normal appearing white matter of patients with early multiple sclerosis. Magn Res Imag. 2002;20:383–388. doi: 10.1016/s0730-725x(02)00519-2. [DOI] [PubMed] [Google Scholar]
130.Tavazzi E, Dwyer MG, Weinstock-Guttman B, et al. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. Neuroimage. 2007;36:746–754. doi: 10.1016/j.neuroimage.2007.03.056. [DOI] [PubMed] [Google Scholar]
131.Bakshi R, Dandamudi VS, Neema M, De C, Beimel RA. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis. J Neuroimaging. 2005;15:30S–45S. doi: 10.1177/1051228405283901. [DOI] [PubMed] [Google Scholar]
132.Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006;5:158–170. doi: 10.1016/S1474-4422(06)70349-0. [DOI] [PubMed] [Google Scholar]
133.Anderson VM, Fox NC, Miller DH. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging. 2006;23:605–618. doi: 10.1002/jmri.20550. [DOI] [PubMed] [Google Scholar]
134.Jasperse B, Minneboo A, de Groot V, et al. Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. Arch Neurol. 2007;64:190–194. doi: 10.1001/archneur.64.2.190. [DOI] [PubMed] [Google Scholar]
135.Chard DT, Brex PA, Ciccarelli O, et al. The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol Neurosurg Psychiatry. 2003;74:1551–1554. doi: 10.1136/jnnp.74.11.1551. [DOI] [PMC free article] [PubMed] [Google Scholar]
136.Bermel RA, Puli SR, Rudick RA, et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol. 2005;62:1371–1376. doi: 10.1001/archneur.62.9.1371. [DOI] [PMC free article] [PubMed] [Google Scholar]
137.Sanfilipo MP, Benedict RH, Sharma J, et al. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage. 2005;26:1068–1077. doi: 10.1016/j.neuroimage.2005.03.008. [DOI] [PubMed] [Google Scholar]
138.Beimel RA, Innus MD, Tjoa CW, Bakshi R. Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study. Neuroreport. 2003;14:335–339. doi: 10.1097/00001756-200303030-00008. [DOI] [PubMed] [Google Scholar]
139.Carone DA, Benedict RH, Dwyer MG, et al. Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS. Neuroimage. 2006;29:505–514. doi: 10.1016/j.neuroimage.2005.07.053. [DOI] [PubMed] [Google Scholar]
140.Houtchens MK, Benedict RHB, Killiany R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology (in press). [DOI] [PubMed]
141.Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain. 2004;127:1101–1107. doi: 10.1093/brain/awh126. [DOI] [PubMed] [Google Scholar]
142.Valsasina P, Benedetti B, Rovaris M, et al. Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology. 2005;65:1126–1128. doi: 10.1212/01.wnl.0000178982.53965.70. [DOI] [PubMed] [Google Scholar]
143.Paolillo A, Piattella MC, Pantano P, et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol. 2004;251:432–439. doi: 10.1007/s00415-004-0349-8. [DOI] [PubMed] [Google Scholar]
144.Rudick RA. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging. 2004;14:54S–64S. doi: 10.1177/1051228404266269. [DOI] [PubMed] [Google Scholar]
145.Zivadinov R, Locatelli L, Cookfair D, et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler. 2007;13:490–501. doi: 10.1177/1352458506070446. [DOI] [PubMed] [Google Scholar]
146.Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68:1390–1401. doi: 10.1212/01.wnl.0000260064.77700.fd. [DOI] [PubMed] [Google Scholar]
147.Chen JT, Collins DL, Atkins HL, et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology. 2006;66:1935–1937. doi: 10.1212/01.wnl.0000219816.44094.f8. [DOI] [PubMed] [Google Scholar]
148.Roccatagliata L, Rocca MA, Valsasina P, et al. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult Scler 2007 Apr 27;[Epub ahead of print]. [DOI] [PubMed]
149.Sicotte NL, Giesser BS, Tandon V, et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol. 2007;64:683–688. doi: 10.1001/archneur.64.5.683. [DOI] [PubMed] [Google Scholar]
150.Fox RJ, Fisher E, Tkach J, Lee JC, Cohen JA, Rudick RA. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications. Mult Scler. 2005;11:140–145. doi: 10.1191/1352458505ms1142oa. [DOI] [PubMed] [Google Scholar]
151.Neema M, Stankiewicz J, Arora A, et al. T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimaging. 2007;17:16S–21S. doi: 10.1111/j.1552-6569.2007.00131.x. [DOI] [PubMed] [Google Scholar]
152.Vrenken H, Geurts JJ, Knol DL, et al. Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. Radiology. 2006;240:811–820. doi: 10.1148/radiol.2403050569. [DOI] [PubMed] [Google Scholar]
153.Vrenken H, Rombouts SA, Pouwels PJ, et al. Voxel-based analysis of quantitative Tl maps demonstrates that multiple sclerosis acts throughout the normal-appearing white matter. AJNR Am J Neuroradiol. 2006;27:868–874. [PMC free article] [PubMed] [Google Scholar]
154.Vaithianathar L, Tench CR, Morgan PS, et al. White matter T(1) relaxation time histograms and cerebral atrophy in multiple sclerosis. J Neurol Sci. 2002;197:45–50. doi: 10.1016/s0022-510x(02)00044-8. [DOI] [PubMed] [Google Scholar]
155.Vaithianathar L, Tench CR, Morgan PS, et al. Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis—a quantitative T1 relaxation time mapping approach. J Neurol. 2003;250:307–315. doi: 10.1007/s00415-003-1001-8. [DOI] [PubMed] [Google Scholar]
156.Parry A, Clare S, Jenkinson M, Smith S, Palace J, Matthews PM. White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis. J Neurol. 2002;249:1279–1286. doi: 10.1007/s00415-002-0837-7. [DOI] [PubMed] [Google Scholar]
157.Parry A, Clare S, Jenkinson M, Smith S, Palace J, Matthews PM. MRI brain T1 relaxation time changes in MS patients increase over time in both the white matter and the cortex. J Neuroimaging. 2003;13:234–239. [PubMed] [Google Scholar]
158.Niepel G, Tench CR, Morgan PS, Evangelou N, Auer DP, Constantinescu CS. Deep gray matter and fatigue in MS: A T1 relaxation time study. J Neurol. 2006;253:896–902. doi: 10.1007/s00415-006-0128-9. [DOI] [PubMed] [Google Scholar]
159.Griffin CM, Dehmeshki J, Chard DT, et al. T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis. Mult Scler. 2002;8:211–216. doi: 10.1191/1352458502ms807oa. [DOI] [PubMed] [Google Scholar]
160.Castriota-Scanderbeg A, Fasano F, Filippi M, Caltagirone C. T1 relaxation maps allow differentiation between pathologic tissue subsets in relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 2004;10:556–561. doi: 10.1191/1352458504ms1073oa. [DOI] [PubMed] [Google Scholar]
161.Davies GR, Hadjiprocopis A, Altmann DR, et al. Normal-appearing grey and white matter T1 abnormality in early relapsing-remitting multiple sclerosis: a longitudinal study. Mult Scler. 2007;13:169–177. doi: 10.1177/1352458506070726. [DOI] [PubMed] [Google Scholar]
162.Janardhan V, Suri S, Bakshi R. Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening. Radiology. 2007;244:823–831. doi: 10.1148/radiol.2443051171. [DOI] [PubMed] [Google Scholar]
163.Stankiewicz J, Panter SS, Neema M, et al. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics. 2007;4:371–386. doi: 10.1016/j.nurt.2007.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
164.Brass SD, Chen N, Mulkern R, Bakshi R. Magnetic resonance imaging of iron deposition in neurologic disorders. Top Magn Reson Imaging. 2006;17:31–40. doi: 10.1097/01.rmr.0000245459.82782.e4. [DOI] [PubMed] [Google Scholar]
165.Brass SD, Benedict RH, Weinstock-Guttman B, Munschauer F, Bakshi R. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler. 2006;12:437–444. doi: 10.1191/135248506ms1301oa. [DOI] [PubMed] [Google Scholar]
166.Bakshi R, Benedict RH, Beimel RA, et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol. 2002;59:62–68. doi: 10.1001/archneur.59.1.62. [DOI] [PubMed] [Google Scholar]
167.Tjoa CW, Benedict RH, Weinstock-Guttman B, et al. MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J Neurol Sci. 2005;234:17–24. doi: 10.1016/j.jns.2005.02.009. [DOI] [PubMed] [Google Scholar]
168.Zhang Y, Zabad RK, Wei X, et al. Deep gray matter ‘black T2’ on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis. Mult Scler 2007 Apr 27[Epub ahead of print]. [DOI] [PubMed]
169.Laule C, Vavasour IM, Kolind SH, et al. Magnetic resonance imaging of myelin. Neurotherapeutics. 2007;4:460–484. doi: 10.1016/j.nurt.2007.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
170.Laule C, Vavasour IM, Moore GRW, et al. Water content and myelin water fraction in multiple sclerosis: a T2 relaxation study. J Neurol. 2004;251:284–293. doi: 10.1007/s00415-004-0306-6. [DOI] [PubMed] [Google Scholar]
171.Laule C, Leung E, Li DKB, et al. Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology. Mult Scler. 2006;12:747–753. doi: 10.1177/1352458506070928. [DOI] [PubMed] [Google Scholar]
172.MacKay A, Whittall K, Adler J, Li D, Paty D, Graeb D. In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med. 1994;31:673–677. doi: 10.1002/mrm.1910310614. [DOI] [PubMed] [Google Scholar]
173.Moore GR, Leung E, MacKay AL, et al. A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain. Neurology. 2000;55:1506–1510. doi: 10.1212/wnl.55.10.1506. [DOI] [PubMed] [Google Scholar]
174.Oh J, Han ET, Lee MC, Nelson SJ, Pelletier D. Multislice brain myelin water fractions at 3T in multiple sclerosis. J Neuroimaging. 2007;17:156–163. doi: 10.1111/j.1552-6569.2007.00098.x. [DOI] [PubMed] [Google Scholar]
175.Ikuta F, Zimmerman HM. Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States. Neurology. 1976;26:26–28. doi: 10.1212/wnl.26.6_part_2.26. [DOI] [PubMed] [Google Scholar]
176.Dalton CM, Brex PA, Miszkiel KA, et al. Spinal cord MRI in clinically isolated optic neuritis. J Neurol Neurosurg Psychiatry. 2003;74:1577–1580. doi: 10.1136/jnnp.74.11.1577. [DOI] [PMC free article] [PubMed] [Google Scholar]
177.Gilmore CP, Bo L, Owens T, Lowe J, Esiri MM, Evangelou N. Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology. Brain Pathol. 2006;16:202–208. doi: 10.1111/j.1750-3639.2006.00018.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
178.Tench CR, Morgan PS, Jaspan T, et al. Spinal cord imaging in multiple sclerosis. J Neuroimaging. 2005;15:94S–102S. doi: 10.1177/1051228405283292. [DOI] [PubMed] [Google Scholar]
179.Nijeholt GJ, van Walderveen MA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain. 1998;121:687–697. doi: 10.1093/brain/121.4.687. [DOI] [PubMed] [Google Scholar]
180.Losseff NA, Webb SL, O’Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain. 1996;119:701–708. doi: 10.1093/brain/119.3.701. [DOI] [PubMed] [Google Scholar]
181.Carbonell-Caballero J, Manjon JV, Marti-Bonmati L, et al. Accurate quantification methods to evaluate cervical cord atrophy in multiple sclerosis patients. MAGMA. 2006;19:237–246. doi: 10.1007/s10334-006-0052-0. [DOI] [PubMed] [Google Scholar]
182.Maier SE. Examination of spinal cord tissue architecture with magnetic resonance diffusion tensor imaging. Neurotherapeutics. 2007;4:453–459. doi: 10.1016/j.nurt.2007.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
183.Agosta F, Absinta M, Sormani MP, et al. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain. 2007;130:2211–2219. doi: 10.1093/brain/awm110. [DOI] [PubMed] [Google Scholar]
184.Ohgiya Y, Oka M, Hiwatashi A, et al. Diffusion tensor MR imaging of the cervical spinal cord in patients with multiple sclerosis. Eur Radiol 2007 May 16;[Epub ahead of print]. [DOI] [PubMed]
185.Hesseltine SM, Law M, Babb J, et al. Diffusion tensor imaging in multiple sclerosis: assessment of regional differences in the axial plane within normal-appearing cervical spinal cord. AJNR Am J Neuroradiol. 2006;27:1189–1193. [PMC free article] [PubMed] [Google Scholar]
186.Kendi AT, Tan FU, Kendi M, et al. MR spectroscopy of cervical spinal cord in patients with multiple sclerosis. Neuroradiology. 2004;46:764–769. doi: 10.1007/s00234-004-1231-1. [DOI] [PubMed] [Google Scholar]
187.Marliani AF, Clementi V, Albini-Riccioli L, Agati R, Leonardi M. Quantitative proton magnetic resonance spectroscopy of the human cervical spinal cord at 3 Tesla. Magn Reson Med. 2007;57:160–163. doi: 10.1002/mrm.21113. [DOI] [PubMed] [Google Scholar]
188.Filippi M, Bozzali M, Horsfield MA, et al. A conventional and magnetization transfer MRI study of the cervical cord in patients with MS. Neurology. 2000;54:207–213. doi: 10.1212/wnl.54.1.207. [DOI] [PubMed] [Google Scholar]
189.Rovaris M, Gallo A, Riva R, et al. An MT MRI study of the cervical cord in clinically isolated syndromes suggestive of MS. Neurology. 2004;63:584–585. doi: 10.1212/01.wnl.0000133209.76642.ef. [DOI] [PubMed] [Google Scholar]
190.Keiper MD, Grossman RI, Hirsch JA, et al. MR identification of white matter abnormalities in multiple sclerosis: A comparison between 1.5 T and 4 T. AJNR Am J Neuroradiology. 1998;19:1489–1493. [PMC free article] [PubMed] [Google Scholar]
191.Kangarlu A, Bourekas EC, Ray-Chaudhury A, Rammohan KW. Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol. 2007;28:262–266. [PMC free article] [PubMed] [Google Scholar]
192.Sicotte NL, Voskuhl RR, Bouvier S, et al. Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Invest Radiol. 2003;38:423–427. doi: 10.1097/01.RLI.0000065426.07178.f1. [DOI] [PubMed] [Google Scholar]
193.Wattjes MP, Harzheim M, Kuhl CK, et al. Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic MR imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol. 2006;27:1794–1798. [PMC free article] [PubMed] [Google Scholar]
194.Wattjes MP, Lutterbey GG, Harzheim M, et al. Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol. 2006;16:2067–2073. doi: 10.1007/s00330-006-0195-4. [DOI] [PubMed] [Google Scholar]
195.Bachmann R, Reilmann R, Schwindt W, Kugel H, Heindel W, Krämer S. FLAIR imaging for multiple sclerosis: a comparative MR study at 1.5 and 3.0 Tesla. Eur Radiol. 2006;16:915–921. doi: 10.1007/s00330-005-0070-8. [DOI] [PubMed] [Google Scholar]
196.Smith SA, Farrell JA, Jones CK, et al. Pulsed magnetization transfer imaging with body coil transmission at 3 Tesla: feasibility and application. Magn Reson Med. 2006;56:866–875. doi: 10.1002/mrm.21035. [DOI] [PubMed] [Google Scholar]
197.Weintraub MI, Khoury A, Cole SP. Biologic effects of 3 Tesla (T) MR imaging comparing traditional 1.5 T and 0.6 T in 1023 consecutive outpatients. J Neuroimaging. 2007;17:241–245. doi: 10.1111/j.1552-6569.2007.00118.x. [DOI] [PubMed] [Google Scholar]

[CR1] 1.Bakshi R, Minagar A, Jaisani Z, Wolinsky JS. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx. 2005;2:277–303. doi: 10.1602/neurorx.2.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR2] 2.Filippi M, Rocca MA. Conventional MRI in multiple sclerosis. J Neuroimaging. 2007;17:3S–9S. doi: 10.1111/j.1552-6569.2007.00129.x. [DOI] [PubMed] [Google Scholar]

[CR3] 3.Zivadinov R, Leist TP. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging. 2005;15:10S–21S. doi: 10.1177/1051228405283291. [DOI] [PubMed] [Google Scholar]

[CR4] 4.Hickman SJ. Optic nerve imaging in multiple sclerosis. J Neuroimaging. 2007;17:42S–45S. doi: 10.1111/j.1552-6569.2007.00136.x. [DOI] [PubMed] [Google Scholar]

[CR5] 5.Cagnin A, Kassiou M, Meikle SR, Banati RB. Positron emission tomography imaging of neuroinflammation. Neurotherapeutics. 2007;4:443–452. doi: 10.1016/j.nurt.2007.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR6] 6.Buckle GJ. Functional magnetic resonance imaging and multiple sclerosis: the evidence for neuronal plasticity. J Neuroimaging. 2005;15:82S–93S. doi: 10.1177/1051228405284093. [DOI] [PubMed] [Google Scholar]

[CR7] 7.Meier DS, Weiner HL, Guttmann CR. Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential? Neurotherapeutics. 2007;4:485–498. doi: 10.1016/j.nurt.2007.05.008. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR8] 8.Patola WB, Coulter BA, Chipperfield PM, Lingawi SS. A comparison of conventional spin-echo and fast spin-echo in the detection of multiple sclerosis. J Magn Reson Imaging. 2001;13:657–667. doi: 10.1002/jmri.1093. [DOI] [PubMed] [Google Scholar]

[CR9] 9.Bakshi R, Ariyaratana S, Benedict RH, Jacobs L. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch Neurol. 2001;58:742–748. doi: 10.1001/archneur.58.5.742. [DOI] [PubMed] [Google Scholar]

[CR10] 10.Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology. 2005;236:254–260. doi: 10.1148/radiol.2361040450. [DOI] [PubMed] [Google Scholar]

[CR11] 11.Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology. 2007;68:634–642. doi: 10.1212/01.wnl.0000250267.85698.7a. [DOI] [PubMed] [Google Scholar]

[CR12] 12.Wattjes MP, Lutterbey GG, Harzheim M, et al. Imaging of inflammatory lesions at 3.0 Tesla in patients with clinically isolated syndromes suggestive of multiple sclerosis: a comparison of fluid-attenuated inversion recovery with T2 turbo spin-echo. Eur Radiol. 2006;16:1494–1500. doi: 10.1007/s00330-005-0082-4. [DOI] [PubMed] [Google Scholar]

[CR13] 13.Wattjes MP, Lutterbey GG, Gieseke J, et al. Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol. 2007;28:54–59. [PMC free article] [PubMed] [Google Scholar]

[CR14] 14.Fillippi M, Yousri T, Baratti C, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 1994;44:635–641. doi: 10.1212/wnl.44.4.635. [DOI] [PubMed] [Google Scholar]

[CR15] 15.Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120:2059–2069. doi: 10.1093/brain/120.11.2059. [DOI] [PubMed] [Google Scholar]

[CR16] 16.O’Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain. 1998;121:495–503. doi: 10.1093/brain/121.3.495. [DOI] [PubMed] [Google Scholar]

[CR17] 17.Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346:158–164. doi: 10.1056/NEJMoa011341. [DOI] [PubMed] [Google Scholar]

[CR18] 18.Gauthier SA, Mandel M, Guttmann CR, et al. Predicting short-term disability in multiple sclerosis. Neurology. 2007;68:2059–2065. doi: 10.1212/01.wnl.0000264890.97479.b1. [DOI] [PubMed] [Google Scholar]

[CR19] 19.Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol. 2006;60:236–242. doi: 10.1002/ana.20883. [DOI] [PubMed] [Google Scholar]

[CR20] 20.Li DK, Held U, Petkau J, et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology. 2006;66:1384–1389. doi: 10.1212/01.wnl.0000210506.00078.5c. [DOI] [PubMed] [Google Scholar]

[CR21] 21.Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Brueck W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol. 2001;49:793–796. doi: 10.1002/ana.1053. [DOI] [PubMed] [Google Scholar]

[CR22] 22.Fisher E, Chang A, Fox RJ, et al. Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 2007 Apr 111;[Epub ahead of print]. [DOI] [PubMed]

[CR23] 23.Paolillo A, Pozzilli C, Gasperini C, et al. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disability. J Neurol Sci. 2000;174:85–91. doi: 10.1016/s0022-510x(00)00259-8. [DOI] [PubMed] [Google Scholar]

[CR24] 24.Sailer M, Losseff NA, Wang L, et al. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis: a prospective 18 months follow-up study. Eur J Neurol. 2001;8:37–42. doi: 10.1046/j.1468-1331.2001.00147.x. [DOI] [PubMed] [Google Scholar]

[CR25] 25.Adams H-P, Wagner S, Sobel SF, et al. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. Eur Neurol. 1999;42:52–63. doi: 10.1159/000008069. [DOI] [PubMed] [Google Scholar]

[CR26] 26.Molyneux PD, Brex PA, Fogg C, et al. The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study. Mult Scler. 2000;6:237–240. doi: 10.1177/135245850000600405. [DOI] [PubMed] [Google Scholar]

[CR27] 27.Datta S, Sajja BR, He R, Wolinsky JS, Gupta RK, Narayana PA. Segmentation and quantification of black holes in multiple sclerosis. Neuroimage. 2006;29:467–474. doi: 10.1016/j.neuroimage.2005.07.042. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR28] 28.Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions (“black holes”) on T1 spinecho MRI correlates with disease progression in multiple sclerosis. Neurology. 1996;47:1469–1476. doi: 10.1212/wnl.47.6.1469. [DOI] [PubMed] [Google Scholar]

[CR29] 29.van Walderveen MA, Lycklama A, Nijeholt GJ, et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol. 2001;58:76–81. doi: 10.1001/archneur.58.1.76. [DOI] [PubMed] [Google Scholar]

[CR30] 30.Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain. 2003;126:1782–1789. doi: 10.1093/brain/awg182. [DOI] [PubMed] [Google Scholar]

[CR31] 31.van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol. 1998;19:675–683. [PMC free article] [PubMed] [Google Scholar]

[CR32] 32.Brack W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 1997;42:783–793. doi: 10.1002/ana.410420515. [DOI] [PubMed] [Google Scholar]

[CR33] 33.Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain. 1997;120:1149–1161. doi: 10.1093/brain/120.7.1149. [DOI] [PubMed] [Google Scholar]

[CR34] 34.Simon JH, Li D, Traboulsee A, Coyle PK, et al. Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol. 2006;27:455–461. [PMC free article] [PubMed] [Google Scholar]

[CR35] 35.Wolansky LJ, Haghighi MH, Sevdalis E, et al. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial. J Neuroimaging. 2005;15:289–290. doi: 10.1177/1051228405277339. [DOI] [PubMed] [Google Scholar]

[CR36] 36.Datta S, Sajja BR, He R, Gupta RK, Wolinsky JS, Narayana PA. Segmentation of gadolinium-enhanced lesions on MRI in multiple sclerosis. J Magn Reson Imaging. 2007;25:932–937. doi: 10.1002/jmri.20896. [DOI] [PubMed] [Google Scholar]

[CR37] 37.Cotton F, Weiner HL, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology. 2003;60:640–646. doi: 10.1212/01.wnl.0000046587.83503.1e. [DOI] [PubMed] [Google Scholar]

[CR38] 38.Masdeu JC, Moreira J, Trasi S, Visintainer P, Cavaliere R, Grundman M. The open ring: a new imaging sign in demyelinating disease. J Neuroimaging. 1996;6:104–107. doi: 10.1111/jon199662104. [DOI] [PubMed] [Google Scholar]

[CR39] 39.Rovira A, Alonso J, Cucurella G, et al. Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. AJNR Am J Neuroradiol. 1999;20:1939–1945. [PMC free article] [PubMed] [Google Scholar]

[CR40] 40.Roychowdhury S, Maldjian JA, Grossman RI. Multiple sclerosis: comparison of trace apparent diffusion coefficients with MR enhancement pattern of lesions. AJNR Am J Neuroradiol. 2000;21:869–874. [PMC free article] [PubMed] [Google Scholar]

[CR41] 41.Minneboo A, Uitdehaag BM, Ader HJ, Barkhof F, Polman CH, Castelijns JA. Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. Neurology. 2005;65:56–61. doi: 10.1212/01.wnl.0000167538.24338.bb. [DOI] [PubMed] [Google Scholar]

[CR42] 42.Leist TP, Gobbini MI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol. 2001;58:57–60. doi: 10.1001/archneur.58.1.57. [DOI] [PubMed] [Google Scholar]

[CR43] 43.Silver NC, Tofts PS, Symms MR, et al. Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult Scler. 2001;7:75–82. doi: 10.1177/135245850100700201. [DOI] [PubMed] [Google Scholar]

[CR44] 44.Soon D, Tozer DJ, Altmann DR, Tofts PS, Miller DH. Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes. Mult Scler 2007 Apr 27;[Epub ahead of print]. [DOI] [PubMed]

[CR45] 45.McFarland HF, Stone LA, Calabresi PA, Maloni H, Bash CN, Frank JA. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Mult Scler. 1996;2:198–205. doi: 10.1177/135245859600200406. [DOI] [PubMed] [Google Scholar]

[CR46] 46.Rashid W, Davies GR, Chard DT, et al. Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study. Mult Scler. 2007;13:178–185. doi: 10.1177/1352458506070758. [DOI] [PubMed] [Google Scholar]

[CR47] 47.Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet. 1999;353:964–969. doi: 10.1016/s0140-6736(98)03053-0. [DOI] [PubMed] [Google Scholar]

[CR48] 48.Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol. 1998;43:332–339. doi: 10.1002/ana.410430311. [DOI] [PubMed] [Google Scholar]

[CR49] 49.Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimenglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 1993;33:480–489. doi: 10.1002/ana.410330511. [DOI] [PubMed] [Google Scholar]

[CR50] 50.Deloire MS, Touil T, Brochet B, Dousset V, Caille JM, Petry KG. Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. Mult Scler. 2004;10:540–548. doi: 10.1191/1352458504ms1090oa. [DOI] [PubMed] [Google Scholar]

[CR51] 51.Petry KG, Boiziau C, Dousset V, Brochet B. Magnetic resonance imaging of human brain macrophage infiltration. Neurotherapeutics. 2007;4:434–442. doi: 10.1016/j.nurt.2007.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR52] 52.Dousset V, Brochet B, Deloire MS, et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol. 2006;27:1000–1005. [PMC free article] [PubMed] [Google Scholar]

[CR53] 53.McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–127. doi: 10.1002/ana.1032. [DOI] [PubMed] [Google Scholar]

[CR54] 54.Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.”. Ann Neurol. 2005;58:840–846. doi: 10.1002/ana.20703. [DOI] [PubMed] [Google Scholar]

[CR55] 55.Lin A, Ross BD, Harris K, et al. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx. 2005;2:197–214. doi: 10.1602/neurorx.2.2.197. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR56] 56.Rosen Y, Lenkinski RE. Recent advances in magnetic resonance neurospectroscopy. Neurotherapeutics. 2007;4:330–345. doi: 10.1016/j.nurt.2007.04.009. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR57] 57.Narayana PA. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging. 2005;15:46S–57S. doi: 10.1177/1051228405284200. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR58] 58.De Stefano N, Filippi M. MR spectroscopy in multiple sclerosis. J Neuroimaging. 2007;17:31S–35S. doi: 10.1111/j.1552-6569.2007.00134.x. [DOI] [PubMed] [Google Scholar]

[CR59] 59.Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 1994;117:49–58. doi: 10.1093/brain/117.1.49. [DOI] [PubMed] [Google Scholar]

[CR60] 60.Husted CA, Goodin DS, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol. 1994;36:157–165. doi: 10.1002/ana.410360207. [DOI] [PubMed] [Google Scholar]

[CR61] 61.Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain. 2005;128:1016–1025. doi: 10.1093/brain/awh467. [DOI] [PubMed] [Google Scholar]

[CR62] 62.De Stefano N, Matthews PM, Antel JP, et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol. 1995;38:901–909. doi: 10.1002/ana.410380610. [DOI] [PubMed] [Google Scholar]

[CR63] 63.Narayana PA, Doyle TJ, Lai D, et al. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol. 1998;43:56–71. doi: 10.1002/ana.410430112. [DOI] [PubMed] [Google Scholar]

[CR64] 64.Narayanan S, Fu L, Pioro E, De Stefano N, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol. 1997;41:385–391. doi: 10.1002/ana.410410314. [DOI] [PubMed] [Google Scholar]

[CR65] 65.Gonen O, Obemdorfer TA, Inglese M, Babb JS, Herbert J, Grossman RI. Reproducibility of three whole-brain N-acetylaspartate decline cohorts in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2007;28:267–271. [PMC free article] [PubMed] [Google Scholar]

[CR66] 66.Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain. 2004;127:1361–1369. doi: 10.1093/brain/awh153. [DOI] [PubMed] [Google Scholar]

[CR67] 67.Wylezinska M, Cifelli A, Jezzard P, Palace J, Alecci M, Matthews PM. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology. 2003;60:1949–1954. doi: 10.1212/01.wnl.0000069464.22267.95. [DOI] [PubMed] [Google Scholar]

[CR68] 68.Sharma R, Narayana PA, Wolinsky JS. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler. 2001;7:221–226. doi: 10.1177/135245850100700402. [DOI] [PubMed] [Google Scholar]

[CR69] 69.Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain. 2002;125:2342–2352. doi: 10.1093/brain/awf240. [DOI] [PubMed] [Google Scholar]

[CR70] 70.Sastre-Garriga J, Ingle GT, Chard DT, et al. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol. 2005;62:569–573. doi: 10.1001/archneur.62.4.569. [DOI] [PubMed] [Google Scholar]

[CR71] 71.De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain. 1998;121:1469–1477. doi: 10.1093/brain/121.8.1469. [DOI] [PubMed] [Google Scholar]

[CR72] 72.De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001;58:65–70. doi: 10.1001/archneur.58.1.65. [DOI] [PubMed] [Google Scholar]

[CR73] 73.Bonneville F, Moriarty DM, Li BS, Babb JS, Grossman RI, Gonen O. Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2002;233:371–375. [PMC free article] [PubMed] [Google Scholar]

[CR74] 74.Pan JW, Krupp LB, Elkins LE, Coyle PK. Cognitive dysfunction lateralizes with NAA in multiple sclerosis. Appl Neuropsychol. 2001;8:155–160. doi: 10.1207/S15324826AN0803_4. [DOI] [PubMed] [Google Scholar]

[CR75] 75.Ruiz-Pena JL, Pinero P, Sellers G, et al. Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy. BMC Neurol. 2004;4:8–8. doi: 10.1186/1471-2377-4-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR76] 76.Gadea M, Martinez-Bisbal MC, Marti-Bonmati L, et al. Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain. 2004;127:89–98. doi: 10.1093/brain/awh002. [DOI] [PubMed] [Google Scholar]

[CR77] 77.Mathiesen HK, Jonsson A, Tscheming T, et al. Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol. 2006;63:533–536. doi: 10.1001/archneur.63.4.533. [DOI] [PubMed] [Google Scholar]

[CR78] 78.Christodoulou C, Krupp LB, Liang Z, et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology. 2003;60:1793–1798. doi: 10.1212/01.wnl.0000072264.75989.b8. [DOI] [PubMed] [Google Scholar]

[CR79] 79.Horsfield MA. Magnetization transfer imaging in multiple sclerosis. J Neuroimaging. 2005;15:58S–67S. doi: 10.1177/1051228405282242. [DOI] [PubMed] [Google Scholar]

[CR80] 80.Filippi M, Rocca MA. Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve. Neurotherapeutics. 2007;4:401–413. doi: 10.1016/j.nurt.2007.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR81] 81.Hiehle JF, Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium enhanced spinecho images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol. 1995;16:69–77. [PMC free article] [PubMed] [Google Scholar]

[CR82] 82.Karampekios S, Papanikolaou N, Papadaki E, et al. Quantification of magnetization transfer rate and native T1 relaxation time of the brain: correlation with magnetization transfer ratio measurements in patients with multiple sclerosis. Neuroradiology. 2005;47:189–196. doi: 10.1007/s00234-005-1344-1. [DOI] [PubMed] [Google Scholar]

[CR83] 83.Rocca MA, Mastronardo G, Rodegher M, et al. Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. AJNR Am J Neuroradiol. 1999;20:821–827. [PMC free article] [PubMed] [Google Scholar]

[CR84] 84.Iannucci G, Tortorella C, Rovaris M, et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol. 2000;21:1034–1038. [PMC free article] [PubMed] [Google Scholar]

[CR85] 85.De Stefano N, Battaglini M, Stromillo ML, et al. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain. 2006;129:2008–2016. doi: 10.1093/brain/awl152. [DOI] [PubMed] [Google Scholar]

[CR86] 86.Pike GB, De Stefano N, Narayanan S, et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology. 2000;215:824–830. doi: 10.1148/radiology.215.3.r00jn02824. [DOI] [PubMed] [Google Scholar]

[CR87] 87.Silver NC, Lai M, Symms MR, Barker GJ, et al. Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology. 1998;51:758–764. doi: 10.1212/wnl.51.3.758. [DOI] [PubMed] [Google Scholar]

[CR88] 88.Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol. 1998;43:809–814. doi: 10.1002/ana.410430616. [DOI] [PubMed] [Google Scholar]

[CR89] 89.van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999;46:747–754. doi: 10.1002/1531-8249(199911)46:5<747::aid-ana10>3.3.co;2-w. [DOI] [PubMed] [Google Scholar]

[CR90] 90.Chen JT, Kuhlmann T, Jansen GH, et al. Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage. 2007;36:1152–1158. doi: 10.1016/j.neuroimage.2007.03.073. [DOI] [PubMed] [Google Scholar]

[CR91] 91.Filippi M, Campi A, Dousset V, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology. 1995;45:478–482. doi: 10.1212/wnl.45.3.478. [DOI] [PubMed] [Google Scholar]

[CR92] 92.Loevner LA, Grossman RI, Cohen JA, Lexa FJ, Kessler D, Kolson DL. Microscopic disease in normal-appearing white matter on conventional MR imaging in patients with multiple sclerosis: assessment with magnetization-transfer measurements. Radiology. 1995;196:511–515. doi: 10.1148/radiology.196.2.7617869. [DOI] [PubMed] [Google Scholar]

[CR93] 93.Ramio-Torrenta L, Sastre-Garriga J, Ingle GT, et al. Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry. 2006;77:40–45. doi: 10.1136/jnnp.2004.052316. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR94] 94.Vrenken H, Geurts JJ, Knol DL, et al. Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis. AJNR Am J Neuroradiol. 2006;27:2005–2011. [PMC free article] [PubMed] [Google Scholar]

[CR95] 95.Richert ND, Ostuni JL, Bash CN, Duyn JH, McFarland HF, Frank JA. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR Am J Neuroradiol. 1998;19:1705–1713. [PMC free article] [PubMed] [Google Scholar]

[CR96] 96.Ge Y, Grossman RI, Udupa JK, et al. Magnetization transfer ratio histogram analysis of gray matter in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2001;22:470–475. [PMC free article] [PubMed] [Google Scholar]

[CR97] 97.Audoin B, Davies G, Rashid W, Fisniku L, Thompson AJ, Miller DH. Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis. Mult Scler. 2007;13:483–489. doi: 10.1177/1352458506070450. [DOI] [PubMed] [Google Scholar]

[CR98] 98.Fernando KT, Tozer DJ, Miszkiel KA, et al. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain. 2005;128:2911–2925. doi: 10.1093/brain/awh654. [DOI] [PubMed] [Google Scholar]

[CR99] 99.Davies GR, Ramio-Torrenta L, Hadjiprocopis A, et al. Evidence for gray matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004;75:998–1002. doi: 10.1136/jnnp.2003.021915. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR100] 100.Sharma J, Zivadinov R, Jaisani Z, et al. A magnetization transfer MRI study of deep gray matter involvement in multiple sclerosis. J Neuroimaging. 2006;16:302–310. doi: 10.1111/j.1552-6569.2006.00054.x. [DOI] [PubMed] [Google Scholar]

[CR101] 101.Oreja-Guevara C, Charil A, Caputo D, Cavarretta R, Sormani MP, Filippi M. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis. Arch Neurol. 2006;63:736–740. doi: 10.1001/archneur.63.5.736. [DOI] [PubMed] [Google Scholar]

[CR102] 102.Iannucci G, Minicucci L, Rodegher M, et al. Correlations between clinical and MRI involvement in multiple sclerosis: assessment using T(1), T(2) and MT histograms. J Neurol Sci. 1999;171:121–129. doi: 10.1016/s0022-510x(99)00259-2. [DOI] [PubMed] [Google Scholar]

[CR103] 103.Davies GR, Altmann DR, Rashid W, et al. Emergence of thalamic magnetization transfer ratio abnormality in early relapsing-remitting multiple sclerosis. Mult Scler. 2005;11:276–281. doi: 10.1191/1352458505ms1166oa. [DOI] [PubMed] [Google Scholar]

[CR104] 104.Khaleeli Z, Sastre-Garriga J, Ciccarelli O, Miller DH, Thompson AJ. Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over one year in early primary progressive MS. J Neurol Neurosurg Psychiatry 2007 Feb 7;[Epub ahead of print]. [DOI] [PMC free article] [PubMed]

[CR105] 105.van Buchem MA, Grossman RI, Armstrong C, et al. Correlation of volumetric magnetization transfer imaging with clinical data in MS. Neurology. 1998;50:1609–1617. doi: 10.1212/wnl.50.6.1609. [DOI] [PubMed] [Google Scholar]

[CR106] 106.Filippi M, Tortorella C, Rovaris M, et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68:157–161. doi: 10.1136/jnnp.68.2.157. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR107] 107.Cox D, Pelletier D, Genain C, et al. The unique impact of changes in normal appearing brain tissue on cognitive dysfunction in secondary progressive multiple sclerosis patients. Mult Scler. 2004;10:626–629. doi: 10.1191/1352458504ms1095oa. [DOI] [PubMed] [Google Scholar]

[CR108] 108.Ranjeva JP, Audoin B, Au Duong MV, et al. Local tissue damage assessed with statistical mapping analysis of brain magnetization transfer ratio: relationship with functional status of patients in the earliest stage of multiple sclerosis. AJNR Am J Neuroradiol. 2005;26:119–127. [PMC free article] [PubMed] [Google Scholar]

[CR109] 109.Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain. 2006;129:2620–2627. doi: 10.1093/brain/awl208. [DOI] [PubMed] [Google Scholar]

[CR110] 110.Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. Neurotherapeutics. 2007;4:316–329. doi: 10.1016/j.nurt.2007.05.011. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR111] 111.Goldberg-Zimring D, Mewes AU, Maddah M, Warfield SK. Diffusion tensor magnetic resonance imaging in multiple sclerosis. J Neuroimaging. 2005;15:68–81. doi: 10.1177/1051228405283363. [DOI] [PubMed] [Google Scholar]

[CR112] 112.Horsfield MA, Lai M, Webb SL, et al. Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance. Magn Reson Med. 1996;36:393–400. doi: 10.1002/mrm.1910360310. [DOI] [PubMed] [Google Scholar]

[CR113] 113.Bammer R, Augustin M, Strasser-Fuchs S, et al. Magnetic resonance diffusion tensor imaging for characterizing diffuse and focal white matter abnormalities in multiple sclerosis. Magn Reson Med. 2000;44:583–591. doi: 10.1002/1522-2594(200010)44:4<583::aid-mrm12>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]

[CR114] 114.Wening DJ, Brassat D, Droogan AG, et al. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain. 2000;123:1667–1676. doi: 10.1093/brain/123.8.1667. [DOI] [PubMed] [Google Scholar]

[CR115] 115.Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology. 2001;56:304–11. doi: 10.1212/wnl.56.3.304. [DOI] [PubMed] [Google Scholar]

[CR116] 116.Schmierer K, Wheeler-Kingshott CA, Boulby PA, et al. Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage. 2007;35:467–477. doi: 10.1016/j.neuroimage.2006.12.010. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR117] 117.Henry RG, Oh J, Nelson SJ, Pelletier D. Directional diffusion in relapsing-remitting multiple sclerosis: a possible in vivo signature of Wallerian degeneration. J Magn Reson Imaging. 2003;8:420–426. doi: 10.1002/jmri.10379. [DOI] [PubMed] [Google Scholar]

[CR118] 118.Ciccarelli O, Wening DJ, Wheeler-Kingshott CA, et al. Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology. 2001;56:926–933. doi: 10.1212/wnl.56.7.926. [DOI] [PubMed] [Google Scholar]

[CR119] 119.Ceccarelli A, Rocca MA, Falini A, et al. Normal-appearing white and grey matter damage in MS: A volumetric and diffusion tensor MRI study at 3.0 Tesla. J Neurol. 2007;254:513–518. doi: 10.1007/s00415-006-0408-4. [DOI] [PubMed] [Google Scholar]

[CR120] 120.Coombs BD, Best A, Brown MS, et al. Multiple sclerosis pathology in the normal and abnormal appearing white matter of the corpus callosum by diffusion tensor imaging. Mult Scler. 2004;10:392–397. doi: 10.1191/1352458504ms1053oa. [DOI] [PubMed] [Google Scholar]

[CR121] 121.Cader S, Johansen-Berg H, Wylezinska M, et al. Discordant white matter N-acetylasparate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis. Neuroimage. 2007;36:19–27. doi: 10.1016/j.neuroimage.2007.02.036. [DOI] [PubMed] [Google Scholar]

[CR122] 122.Audoin B, Guye M, Reuter F, et al. Structure of WM bundles constituting the working memory system in early multiple sclerosis: a quantitative DTI tractography study. Neuroimage. 2007;36:1324–1330. doi: 10.1016/j.neuroimage.2007.04.038. [DOI] [PubMed] [Google Scholar]

[CR123] 123.Saindane AM, Law M, Ge Y, et al. Correlation of diffusion tensor and dynamic perfusion MR imaging metrics in normal-appearing corpus callosum: support for primary hypoperfusion in multiple sclerosis. AJNR Am J Neuroradiol. 2007;28:767–772. [PMC free article] [PubMed] [Google Scholar]

[CR124] 124.Wilson M, Tench CR, Morgan PS, Blumhardt LD. Pyramidal tract mapping by diffusion tensor magnetic resonance imaging in multiple sclerosis: improving correlations with disability. J Neurol Neurosurg Psychiatry. 2003;74:203–207. doi: 10.1136/jnnp.74.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR125] 125.Fabiano AJ, Sharma J, Weinstock-Guttman B, Benedict RH, Zivadinov R, Bakshi R. Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. J Neuroimaging. 2003;13:307–314. [PubMed] [Google Scholar]

[CR126] 126.Rovaris M, Gallo A, Valsasina P, et al. Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. Neuroimage. 2005;24:1139–1146. doi: 10.1016/j.neuroimage.2004.10.006. [DOI] [PubMed] [Google Scholar]

[CR127] 127.Droogan AG, Clark CA, Werring DJ, Barker GJ, McDonald WI, Miller DH. Comparison of multiple sclerosis clinical subgroups using navigated spin echo diffusion-weighted imaging. Magn Reson Imaging. 1999;17:653–661. doi: 10.1016/s0730-725x(99)00011-9. [DOI] [PubMed] [Google Scholar]

[CR128] 128.Cercignani M, Iannucci G, Rocca MA, Comi G, Horsfield MA, Filippi M. Pathologic damage in MS assessed by diffusion-weighted and magnetization transfer MRI. Neurology. 2000;54:1139–1144. doi: 10.1212/wnl.54.5.1139. [DOI] [PubMed] [Google Scholar]

[CR129] 129.Caramia F, Pantano P, Di Legge S, et al. A longitudinal study of MR diffusion changes in normal appearing white matter of patients with early multiple sclerosis. Magn Res Imag. 2002;20:383–388. doi: 10.1016/s0730-725x(02)00519-2. [DOI] [PubMed] [Google Scholar]

[CR130] 130.Tavazzi E, Dwyer MG, Weinstock-Guttman B, et al. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. Neuroimage. 2007;36:746–754. doi: 10.1016/j.neuroimage.2007.03.056. [DOI] [PubMed] [Google Scholar]

[CR131] 131.Bakshi R, Dandamudi VS, Neema M, De C, Beimel RA. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis. J Neuroimaging. 2005;15:30S–45S. doi: 10.1177/1051228405283901. [DOI] [PubMed] [Google Scholar]

[CR132] 132.Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006;5:158–170. doi: 10.1016/S1474-4422(06)70349-0. [DOI] [PubMed] [Google Scholar]

[CR133] 133.Anderson VM, Fox NC, Miller DH. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging. 2006;23:605–618. doi: 10.1002/jmri.20550. [DOI] [PubMed] [Google Scholar]

[CR134] 134.Jasperse B, Minneboo A, de Groot V, et al. Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. Arch Neurol. 2007;64:190–194. doi: 10.1001/archneur.64.2.190. [DOI] [PubMed] [Google Scholar]

[CR135] 135.Chard DT, Brex PA, Ciccarelli O, et al. The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol Neurosurg Psychiatry. 2003;74:1551–1554. doi: 10.1136/jnnp.74.11.1551. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR136] 136.Bermel RA, Puli SR, Rudick RA, et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol. 2005;62:1371–1376. doi: 10.1001/archneur.62.9.1371. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR137] 137.Sanfilipo MP, Benedict RH, Sharma J, et al. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage. 2005;26:1068–1077. doi: 10.1016/j.neuroimage.2005.03.008. [DOI] [PubMed] [Google Scholar]

[CR138] 138.Beimel RA, Innus MD, Tjoa CW, Bakshi R. Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study. Neuroreport. 2003;14:335–339. doi: 10.1097/00001756-200303030-00008. [DOI] [PubMed] [Google Scholar]

[CR139] 139.Carone DA, Benedict RH, Dwyer MG, et al. Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS. Neuroimage. 2006;29:505–514. doi: 10.1016/j.neuroimage.2005.07.053. [DOI] [PubMed] [Google Scholar]

[CR140] 140.Houtchens MK, Benedict RHB, Killiany R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology (in press). [DOI] [PubMed]

[CR141] 141.Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain. 2004;127:1101–1107. doi: 10.1093/brain/awh126. [DOI] [PubMed] [Google Scholar]

[CR142] 142.Valsasina P, Benedetti B, Rovaris M, et al. Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology. 2005;65:1126–1128. doi: 10.1212/01.wnl.0000178982.53965.70. [DOI] [PubMed] [Google Scholar]

[CR143] 143.Paolillo A, Piattella MC, Pantano P, et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol. 2004;251:432–439. doi: 10.1007/s00415-004-0349-8. [DOI] [PubMed] [Google Scholar]

[CR144] 144.Rudick RA. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging. 2004;14:54S–64S. doi: 10.1177/1051228404266269. [DOI] [PubMed] [Google Scholar]

[CR145] 145.Zivadinov R, Locatelli L, Cookfair D, et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler. 2007;13:490–501. doi: 10.1177/1352458506070446. [DOI] [PubMed] [Google Scholar]

[CR146] 146.Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68:1390–1401. doi: 10.1212/01.wnl.0000260064.77700.fd. [DOI] [PubMed] [Google Scholar]

[CR147] 147.Chen JT, Collins DL, Atkins HL, et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology. 2006;66:1935–1937. doi: 10.1212/01.wnl.0000219816.44094.f8. [DOI] [PubMed] [Google Scholar]

[CR148] 148.Roccatagliata L, Rocca MA, Valsasina P, et al. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult Scler 2007 Apr 27;[Epub ahead of print]. [DOI] [PubMed]

[CR149] 149.Sicotte NL, Giesser BS, Tandon V, et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol. 2007;64:683–688. doi: 10.1001/archneur.64.5.683. [DOI] [PubMed] [Google Scholar]

[CR150] 150.Fox RJ, Fisher E, Tkach J, Lee JC, Cohen JA, Rudick RA. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications. Mult Scler. 2005;11:140–145. doi: 10.1191/1352458505ms1142oa. [DOI] [PubMed] [Google Scholar]

[CR151] 151.Neema M, Stankiewicz J, Arora A, et al. T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimaging. 2007;17:16S–21S. doi: 10.1111/j.1552-6569.2007.00131.x. [DOI] [PubMed] [Google Scholar]

[CR152] 152.Vrenken H, Geurts JJ, Knol DL, et al. Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. Radiology. 2006;240:811–820. doi: 10.1148/radiol.2403050569. [DOI] [PubMed] [Google Scholar]

[CR153] 153.Vrenken H, Rombouts SA, Pouwels PJ, et al. Voxel-based analysis of quantitative Tl maps demonstrates that multiple sclerosis acts throughout the normal-appearing white matter. AJNR Am J Neuroradiol. 2006;27:868–874. [PMC free article] [PubMed] [Google Scholar]

[CR154] 154.Vaithianathar L, Tench CR, Morgan PS, et al. White matter T(1) relaxation time histograms and cerebral atrophy in multiple sclerosis. J Neurol Sci. 2002;197:45–50. doi: 10.1016/s0022-510x(02)00044-8. [DOI] [PubMed] [Google Scholar]

[CR155] 155.Vaithianathar L, Tench CR, Morgan PS, et al. Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis—a quantitative T1 relaxation time mapping approach. J Neurol. 2003;250:307–315. doi: 10.1007/s00415-003-1001-8. [DOI] [PubMed] [Google Scholar]

[CR156] 156.Parry A, Clare S, Jenkinson M, Smith S, Palace J, Matthews PM. White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis. J Neurol. 2002;249:1279–1286. doi: 10.1007/s00415-002-0837-7. [DOI] [PubMed] [Google Scholar]

[CR157] 157.Parry A, Clare S, Jenkinson M, Smith S, Palace J, Matthews PM. MRI brain T1 relaxation time changes in MS patients increase over time in both the white matter and the cortex. J Neuroimaging. 2003;13:234–239. [PubMed] [Google Scholar]

[CR158] 158.Niepel G, Tench CR, Morgan PS, Evangelou N, Auer DP, Constantinescu CS. Deep gray matter and fatigue in MS: A T1 relaxation time study. J Neurol. 2006;253:896–902. doi: 10.1007/s00415-006-0128-9. [DOI] [PubMed] [Google Scholar]

[CR159] 159.Griffin CM, Dehmeshki J, Chard DT, et al. T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis. Mult Scler. 2002;8:211–216. doi: 10.1191/1352458502ms807oa. [DOI] [PubMed] [Google Scholar]

[CR160] 160.Castriota-Scanderbeg A, Fasano F, Filippi M, Caltagirone C. T1 relaxation maps allow differentiation between pathologic tissue subsets in relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 2004;10:556–561. doi: 10.1191/1352458504ms1073oa. [DOI] [PubMed] [Google Scholar]

[CR161] 161.Davies GR, Hadjiprocopis A, Altmann DR, et al. Normal-appearing grey and white matter T1 abnormality in early relapsing-remitting multiple sclerosis: a longitudinal study. Mult Scler. 2007;13:169–177. doi: 10.1177/1352458506070726. [DOI] [PubMed] [Google Scholar]

[CR162] 162.Janardhan V, Suri S, Bakshi R. Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening. Radiology. 2007;244:823–831. doi: 10.1148/radiol.2443051171. [DOI] [PubMed] [Google Scholar]

[CR163] 163.Stankiewicz J, Panter SS, Neema M, et al. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics. 2007;4:371–386. doi: 10.1016/j.nurt.2007.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR164] 164.Brass SD, Chen N, Mulkern R, Bakshi R. Magnetic resonance imaging of iron deposition in neurologic disorders. Top Magn Reson Imaging. 2006;17:31–40. doi: 10.1097/01.rmr.0000245459.82782.e4. [DOI] [PubMed] [Google Scholar]

[CR165] 165.Brass SD, Benedict RH, Weinstock-Guttman B, Munschauer F, Bakshi R. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler. 2006;12:437–444. doi: 10.1191/135248506ms1301oa. [DOI] [PubMed] [Google Scholar]

[CR166] 166.Bakshi R, Benedict RH, Beimel RA, et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol. 2002;59:62–68. doi: 10.1001/archneur.59.1.62. [DOI] [PubMed] [Google Scholar]

[CR167] 167.Tjoa CW, Benedict RH, Weinstock-Guttman B, et al. MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J Neurol Sci. 2005;234:17–24. doi: 10.1016/j.jns.2005.02.009. [DOI] [PubMed] [Google Scholar]

[CR168] 168.Zhang Y, Zabad RK, Wei X, et al. Deep gray matter ‘black T2’ on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis. Mult Scler 2007 Apr 27[Epub ahead of print]. [DOI] [PubMed]

[CR169] 169.Laule C, Vavasour IM, Kolind SH, et al. Magnetic resonance imaging of myelin. Neurotherapeutics. 2007;4:460–484. doi: 10.1016/j.nurt.2007.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR170] 170.Laule C, Vavasour IM, Moore GRW, et al. Water content and myelin water fraction in multiple sclerosis: a T2 relaxation study. J Neurol. 2004;251:284–293. doi: 10.1007/s00415-004-0306-6. [DOI] [PubMed] [Google Scholar]

[CR171] 171.Laule C, Leung E, Li DKB, et al. Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology. Mult Scler. 2006;12:747–753. doi: 10.1177/1352458506070928. [DOI] [PubMed] [Google Scholar]

[CR172] 172.MacKay A, Whittall K, Adler J, Li D, Paty D, Graeb D. In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med. 1994;31:673–677. doi: 10.1002/mrm.1910310614. [DOI] [PubMed] [Google Scholar]

[CR173] 173.Moore GR, Leung E, MacKay AL, et al. A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain. Neurology. 2000;55:1506–1510. doi: 10.1212/wnl.55.10.1506. [DOI] [PubMed] [Google Scholar]

[CR174] 174.Oh J, Han ET, Lee MC, Nelson SJ, Pelletier D. Multislice brain myelin water fractions at 3T in multiple sclerosis. J Neuroimaging. 2007;17:156–163. doi: 10.1111/j.1552-6569.2007.00098.x. [DOI] [PubMed] [Google Scholar]

[CR175] 175.Ikuta F, Zimmerman HM. Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States. Neurology. 1976;26:26–28. doi: 10.1212/wnl.26.6_part_2.26. [DOI] [PubMed] [Google Scholar]

[CR176] 176.Dalton CM, Brex PA, Miszkiel KA, et al. Spinal cord MRI in clinically isolated optic neuritis. J Neurol Neurosurg Psychiatry. 2003;74:1577–1580. doi: 10.1136/jnnp.74.11.1577. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR177] 177.Gilmore CP, Bo L, Owens T, Lowe J, Esiri MM, Evangelou N. Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology. Brain Pathol. 2006;16:202–208. doi: 10.1111/j.1750-3639.2006.00018.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR178] 178.Tench CR, Morgan PS, Jaspan T, et al. Spinal cord imaging in multiple sclerosis. J Neuroimaging. 2005;15:94S–102S. doi: 10.1177/1051228405283292. [DOI] [PubMed] [Google Scholar]

[CR179] 179.Nijeholt GJ, van Walderveen MA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain. 1998;121:687–697. doi: 10.1093/brain/121.4.687. [DOI] [PubMed] [Google Scholar]

[CR180] 180.Losseff NA, Webb SL, O’Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain. 1996;119:701–708. doi: 10.1093/brain/119.3.701. [DOI] [PubMed] [Google Scholar]

[CR181] 181.Carbonell-Caballero J, Manjon JV, Marti-Bonmati L, et al. Accurate quantification methods to evaluate cervical cord atrophy in multiple sclerosis patients. MAGMA. 2006;19:237–246. doi: 10.1007/s10334-006-0052-0. [DOI] [PubMed] [Google Scholar]

[CR182] 182.Maier SE. Examination of spinal cord tissue architecture with magnetic resonance diffusion tensor imaging. Neurotherapeutics. 2007;4:453–459. doi: 10.1016/j.nurt.2007.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR183] 183.Agosta F, Absinta M, Sormani MP, et al. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain. 2007;130:2211–2219. doi: 10.1093/brain/awm110. [DOI] [PubMed] [Google Scholar]

[CR184] 184.Ohgiya Y, Oka M, Hiwatashi A, et al. Diffusion tensor MR imaging of the cervical spinal cord in patients with multiple sclerosis. Eur Radiol 2007 May 16;[Epub ahead of print]. [DOI] [PubMed]

[CR185] 185.Hesseltine SM, Law M, Babb J, et al. Diffusion tensor imaging in multiple sclerosis: assessment of regional differences in the axial plane within normal-appearing cervical spinal cord. AJNR Am J Neuroradiol. 2006;27:1189–1193. [PMC free article] [PubMed] [Google Scholar]

[CR186] 186.Kendi AT, Tan FU, Kendi M, et al. MR spectroscopy of cervical spinal cord in patients with multiple sclerosis. Neuroradiology. 2004;46:764–769. doi: 10.1007/s00234-004-1231-1. [DOI] [PubMed] [Google Scholar]

[CR187] 187.Marliani AF, Clementi V, Albini-Riccioli L, Agati R, Leonardi M. Quantitative proton magnetic resonance spectroscopy of the human cervical spinal cord at 3 Tesla. Magn Reson Med. 2007;57:160–163. doi: 10.1002/mrm.21113. [DOI] [PubMed] [Google Scholar]

[CR188] 188.Filippi M, Bozzali M, Horsfield MA, et al. A conventional and magnetization transfer MRI study of the cervical cord in patients with MS. Neurology. 2000;54:207–213. doi: 10.1212/wnl.54.1.207. [DOI] [PubMed] [Google Scholar]

[CR189] 189.Rovaris M, Gallo A, Riva R, et al. An MT MRI study of the cervical cord in clinically isolated syndromes suggestive of MS. Neurology. 2004;63:584–585. doi: 10.1212/01.wnl.0000133209.76642.ef. [DOI] [PubMed] [Google Scholar]

[CR190] 190.Keiper MD, Grossman RI, Hirsch JA, et al. MR identification of white matter abnormalities in multiple sclerosis: A comparison between 1.5 T and 4 T. AJNR Am J Neuroradiology. 1998;19:1489–1493. [PMC free article] [PubMed] [Google Scholar]

[CR191] 191.Kangarlu A, Bourekas EC, Ray-Chaudhury A, Rammohan KW. Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol. 2007;28:262–266. [PMC free article] [PubMed] [Google Scholar]

[CR192] 192.Sicotte NL, Voskuhl RR, Bouvier S, et al. Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Invest Radiol. 2003;38:423–427. doi: 10.1097/01.RLI.0000065426.07178.f1. [DOI] [PubMed] [Google Scholar]

[CR193] 193.Wattjes MP, Harzheim M, Kuhl CK, et al. Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic MR imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol. 2006;27:1794–1798. [PMC free article] [PubMed] [Google Scholar]

[CR194] 194.Wattjes MP, Lutterbey GG, Harzheim M, et al. Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol. 2006;16:2067–2073. doi: 10.1007/s00330-006-0195-4. [DOI] [PubMed] [Google Scholar]

[CR195] 195.Bachmann R, Reilmann R, Schwindt W, Kugel H, Heindel W, Krämer S. FLAIR imaging for multiple sclerosis: a comparative MR study at 1.5 and 3.0 Tesla. Eur Radiol. 2006;16:915–921. doi: 10.1007/s00330-005-0070-8. [DOI] [PubMed] [Google Scholar]

[CR196] 196.Smith SA, Farrell JA, Jones CK, et al. Pulsed magnetization transfer imaging with body coil transmission at 3 Tesla: feasibility and application. Magn Reson Med. 2006;56:866–875. doi: 10.1002/mrm.21035. [DOI] [PubMed] [Google Scholar]

[CR197] 197.Weintraub MI, Khoury A, Cole SP. Biologic effects of 3 Tesla (T) MR imaging comparing traditional 1.5 T and 0.6 T in 1023 consecutive outpatients. J Neuroimaging. 2007;17:241–245. doi: 10.1111/j.1552-6569.2007.00118.x. [DOI] [PubMed] [Google Scholar]

PERMALINK

MRI in multiple sclerosis: What’s inside the toolbox?

Mohit Neema

James Stankiewicz

Ashish Arora

Zachary D Guss

Rohit Bakshi

Summary

References

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

MRI in multiple sclerosis: What’s inside the toolbox?

Mohit Neema

James Stankiewicz

Ashish Arora

Zachary D Guss

Rohit Bakshi

Summary

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases